Create Free Account

By creating account you will get access to hot stocks & personalised emails

AstraZeneca PLC ADR

Healthcare US AZN

71.625USD
-1.205(1.65%)

Last update at 2024-10-31T18:47:00Z

Day Range

71.1471.92
LowHigh

52 Week Range

59.5579.36
LowHigh

Fundamentals

  • Previous Close 72.83
  • Market Cap243510.92M
  • Volume4522055
  • P/E Ratio38.69
  • Dividend Yield1.85%
  • EBITDA15803.00M
  • Revenue TTM47611.00M
  • Revenue Per Share TTM2.55
  • Gross Profit TTM 35732.00M
  • Diluted EPS TTM2.03

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 2501.00M -265.00000M 3916.00M 1548.00M 1993.00M
Minority interest -5.00000M -3.00000M 16.00M 1469.00M 1576.00M
Net income 3288.00M 112.00M 3196.00M 1335.00M 2155.00M
Selling general administrative 18955.00M 15680.00M 11693.00M 8964.00M 8479.00M
Selling and marketing expenses 18955.00M 15680.00M 11693.00M 11848.00M 10362.00M
Gross profit 31960.00M 24980.00M 21318.00M 19463.00M 17154.00M
Reconciled depreciation 5480.00M 6530.00M 3149.00M 3762.00M 3753.00M
Ebit 3757.00M 1056.00M 5162.00M 2924.00M 3412.00M
Ebitda 9327.00M 7565.00M 8371.00M 7016.00M 7165.00M
Depreciation and amortization 5570.00M 6509.00M 3209.00M 4092.00M 3753.00M
Non operating income net other - - - - -
Operating income 3757.00M 1056.00M 5162.00M 2924.00M 3387.00M
Other operating expenses 40594.00M 36361.00M 21455.00M 21186.00M 18703.00M
Interest expense 1346.00M 1300.00M 1306.00M 1432.00M 1419.00M
Tax provision -792.00000M -380.00000M 772.00M 321.00M -57.00000M
Interest income 95.00M 43.00M 87.00M 774.00M 778.00M
Net interest income -1251.00000M -1257.00000M -1219.00000M -1237.00000M -1228.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -792.00000M -380.00000M 772.00M 321.00M -57.00000M
Total revenue 44351.00M 37417.00M 26617.00M 24384.00M 22090.00M
Total operating expenses 28203.00M 23924.00M 16156.00M 16265.00M 13767.00M
Cost of revenue 12391.00M 12437.00M 5299.00M 4921.00M 4936.00M
Total other income expense net -1256.00000M -1321.00000M -1246.00000M -1376.00000M -1394.00000M
Discontinued operations - - - - -
Net income from continuing ops 3293.00M 115.00M 3144.00M 1227.00M 2050.00M
Net income applicable to common shares 3288.00M 112.00M 3196.00M 1335.00M 2155.00M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 101119.00M 96483.00M 105363.00M 66729.00M 61377.00M
Intangible assets 38089.00M 39307.00M 42387.00M 20947.00M 20833.00M
Earning assets - - - - -
Other current assets 116.00M 11489.00M 105.00M 7528.00M 6152.00M
Total liab 61953.00M 59425.00M 66076.00M 51091.00M 46781.00M
Total stockholder equity 39143.00M 37037.00M 39268.00M 15622.00M 13127.00M
Deferred long term liab - - - - -
Other current liab 21726.00M 1711.00M 1763.00M 2136.00M 2120.00M
Common stock 388.00M 387.00M 387.00M 328.00M 328.00M
Capital stock 388.00M 387.00M 387.00M 328.00M 328.00M
Retained earnings 1502.00M -574.00000M 1710.00M 5299.00M 2812.00M
Other liab - 8499.00M 13011.00M 10491.00M 10283.00M
Good will 20048.00M 19820.00M 19997.00M 11845.00M 11668.00M
Other assets - 4172.00M 5302.00M 4284.00M 3466.00M
Cash 5840.00M 6166.00M 6329.00M 7832.00M 5369.00M
Cash and equivalents - - - - -
Total current liabilities 30542.00M 26293.00M 22594.00M 20307.00M 18117.00M
Current deferred revenue 149.00M - - - -
Net debt 22782.00M 23066.00M 24452.00M 12548.00M 12858.00M
Short term debt 5400.00M 5542.00M 1893.00M 2386.00M 2010.00M
Short long term debt 5129.00M 5314.00M 1660.00M 2194.00M 1822.00M
Short long term debt total 28622.00M 29232.00M 30781.00M 20380.00M 18227.00M
Other stockholder equity 35636.00M 37224.00M 37171.00M 9995.00M 9987.00M
Property plant equipment - 9449.00M 10171.00M 8917.00M 8335.00M
Total current assets 25054.00M 22593.00M 26244.00M 19544.00M 15563.00M
Long term investments - - - - 1512.00M
Net tangible assets - -22090.00000M -23116.00000M -17170.00000M -19374.00000M
Short term investments 20.00M 239.00M 69.00M 160.00M 849.00M
Net receivables 13552.00M 10521.00M 10758.00M 5651.00M 5181.00M
Long term debt 22365.00M 22965.00M 28134.00M 17505.00M 15730.00M
Inventory 5424.00M 4699.00M 8983.00M 4024.00M 3193.00M
Accounts payable 3267.00M 19040.00M 18938.00M 15785.00M 13987.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity 23.00M - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1617.00M - - -8193.00000M -7517.00000M
Additional paid in capital 35341.00M - - - -
Common stock total equity - - - 328.00M 328.00M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock 0.00000M - - - -
Accumulated amortization - - - - -
Non currrent assets other 1051.00M 1148.00M 1066.00M 1051.00M 1650.00M
Deferred long term asset charges - - - - -
Non current assets total 76065.00M 73890.00M 79119.00M 47185.00M 45814.00M
Capital lease obligations 1128.00M 953.00M 987.00M 681.00M 675.00M
Long term debt total - - - - 16217.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2960.00000M 605.00M -285.00000M 125.00M 140.00M
Change to liabilities 1165.00M 1405.00M 1721.00M 868.00M -103.00000M
Total cashflows from investing activities -2960.00000M -11058.00000M -285.00000M -657.00000M 963.00M
Net borrowings -1441.00000M 7654.00M 1440.00M -1702.00000M 1473.00M
Total cash from financing activities -6823.00000M 3649.00M -2203.00000M -1765.00000M -2044.00000M
Change to operating activities - 2021.00M 361.00M 361.00M 361.00M
Net income 2501.00M -265.00000M 3916.00M 1548.00M 1993.00M
Change in cash -55.00000M -1508.00000M 2323.00M 552.00M 1499.00M
Begin period cash flow 6038.00M 7546.00M 5223.00M 4671.00M 3172.00M
End period cash flow 5983.00M 6038.00M 7546.00M 5223.00M 4671.00M
Total cash from operating activities 9808.00M 5963.00M 4799.00M 2969.00M 2618.00M
Issuance of capital stock 29.00M 29.00M 30.00M 3525.00M 34.00M
Depreciation 5480.00M 6530.00M 3149.00M 3762.00M 3753.00M
Other cashflows from investing activities 60.00M 54.00M 87.00M 274.00M 193.00M
Dividends paid -4364.00000M -3856.00000M -3572.00000M -3592.00000M 3484.00M
Change to inventory 3941.00M 1577.00M -621.00000M -316.00000M -13.00000M
Change to account receivables -1349.00000M -961.00000M -739.00000M -898.00000M -523.00000M
Sale purchase of stock -920.00000M 12413.00M 3049.00M 314.00M 2971.00M
Other cashflows from financing activities -297.00000M -178.00000M -101.00000M 4.00M -67.00000M
Change to netincome -2491.00000M -272.00000M -1650.00000M -816.00000M -1709.00000M
Capital expenditures 2571.00M 2200.00M 2606.00M 2460.00M 1371.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 3757.00M 2021.00M 361.00M -346.00000M -639.00000M
Stock based compensation - - - - -
Other non cash items -1930.00000M -2323.00000M -2627.00000M -1995.00000M -2489.00000M
Free cash flow 7237.00M 3763.00M 2193.00M 509.00M 1247.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AZN
AstraZeneca PLC ADR		 -1.205 1.65% 71.62 38.69 16.31 4.67 5.46 5.20 17.74
LLY
Eli Lilly and Company		 -7.22 0.85% 839.61 103.14 46.73 16.88 48.24 17.43 69.11
JNJ
Johnson & Johnson		 -0.37 0.23% 160.24 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 1.42 0.70% 202.92 42.38 13.68 4.88 22.14 5.72 31.93
MRK
Merck & Company Inc		 -1.91 1.82% 102.92 59.83 12.33 4.50 6.47 4.94 23.79

Reports Covered

Stock Research & News

View All

Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC ADR

1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA

Key Executives

Name Title Year Born
Mr. Pascal Soriot D.V.M., M.B.A. CEO & Exec. Director 1959
Dr. Aradhana Sarin M.D. CFO & Exec. Director 1975
Mr. Marc Dunoyer CEO of Alexion & Chief Strategy Officer 1952
Ms. Pam P. Cheng EVP of Operations & Information Technology and Member of External Sustainability Advisory Board 1971
Mr. Chris Sheldon Head of Investor Relations NA
Mr. Jeffrey Pott Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board NA
Ms. Katarina Ageborg EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board NA
Gonzalo Vina Head of Global Media Relations NA
Dr. Menelas Pangalos Ph.D. EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board 1967
Dr. Ruud Dobber Ph.D. Exec. Vice-Pres of BioPharmaceuticals Bus. Unit NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.